Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy ...Middle East

HANGZHOU, China, March 14, 2026 /PRNewswire/ -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as...

Hence then, the article about vimgreen s novel a2ar antagonist receives cde ind approval for nash mash therapy was published today ( Saturday 14/03/2026 - 07:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy )

Also on site :

• Sweden investigates potential e-govt platform hack
• José Leclerc Targeting July Return
• ‘Divine Incursions’ Is a Brainy Monster-of-the-Week Thriller That Will Scratch Your ‘X-Files’ Itch